CALC
CalciMedica, Inc.5.22
+0.59+12.7%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
75.22MP/E (TTM)
-Basic EPS (TTM)
-1.62Dividend Yield
0%Recent Filings
8-K
2025 loss widens; programs advance
CalciMedica reported $29.6M net loss for 2025, up from $13.7M in 2024, with cash at $13.0M funding operations into Q4 2026. KOURAGE Phase 2 in AKI showed no drug-related toxicity despite mortality imbalance from baseline severity differences; FDA talks planned Q2 2026. Auxora AP pivotal design finalizes 1H 2026 post positive FDA feedback. CM5480 preclinical PAH data published; IND eyed 2027. Cash burn accelerates.
10-K
FY2025 results
CalciMedica reported FY2025 ended December 31, 2025 with no revenue as a clinical-stage biopharma, posting net losses from R&D on Auxora and pipeline work—no quarterly breakdowns or financial statements disclosed in the 10-K. CARPO Phase 2b trial in acute pancreatitis showed dose-dependent cuts in time to solid food tolerance and 100% relative risk reduction in new-onset severe respiratory failure for medium/high doses versus placebo. CARDEA Phase 2 in COVID-19 pneumonia cut mortality 56%. No cash flow, debt, or capex details provided. Pivotal AP program design eyed for H1 2026. KOURAGE AKI trial discontinued January 2026 over mortality imbalance. Clinical trial delays threaten momentum.
8-K
Halts KOURAGE trial on safety signal.
CalciMedica discontinued its Phase 2 KOURAGE trial of Auxora in Stage 2/3 AKI with AHRF on January 28, 2026, following IDMC recommendation over a safety concern tied to enrollment criteria. No drug-related deaths or expedited FDA-reportable serious adverse events occurred. The company will analyze unblinded data to rethink AKI strategy. Trial halt shifts focus.
8-K
Discontinues KOURAGE trial
10-Q
Q3 FY2025 results
CalciMedica posted a Q3 operating loss of $5.6M, flat y/y while R&D climbed 9% to $3.9M on clinical trial momentum, offset by 19% G&A cuts. Net loss widened to $7.8M from $5.6M y/y, driven by $2.0M fair-value hit on financial instruments including warrants and the new promissory note. Cash and equivalents fell to $14.1M from $19.7M year-start, after $9.7M Tranche 1 debt draw (Feb 2025, up to $32.5M total, secured by assets, matures Sep 2028 at ≥12.75% rate) and $1.8M ATM equity. Steady burn funds ops into H2 2026. Going concern warning flags funding needs. Clinical delays threaten timelines.
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
CLDI
Calidi Biotherapeutics, Inc.
1.30-0.03
CRMD
CorMedix Inc.
11.44+0.11
DMAC
DiaMedica Therapeutics Inc.
8.76+0.09
EDSA
Edesa Biotech, Inc.
1.49-0.00
KALA
KALA BIO, Inc.
0.56-0.05
KALV
KalVista Pharmaceuticals, Inc.
15.90-1.00
RAPT
RAPT Therapeutics, Inc.
34.03+0.81
ZURA
Zura Bio Limited
4.12+0.05
ZVSA
ZyVersa Therapeutics, Inc.
0.13-0.00